Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours.
about
Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapyNew data concerning the epidemiology of Hepatitis B virus infection in GreeceHepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management.Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis.Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists.The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder systemManagement of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy.When treating cancer, please don't forget hepatitis B.Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors.Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients.Management of hepatitis B reactivation in patients receiving cancer chemotherapy.Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area.Hepatitis B screening before chemotherapy: a survey of practitioners' knowledge, beliefs, and screening practices.Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis.Model of life expectancy of chronic hepatitis B carriers in an endemic region.Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment.PREVALENCE OF OCCULT HEPATITIS B INFECTION IN IRANIAN CANCER PATIENTS BEFORE CHEMOTHERAPY TREATMENT.Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.Management of HBV infection during immunosuppressive treatmentHepatitis B reactivation after chemotherapy: two decades of clinical research.Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients.Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.Lamivudine for chemotherapy-induced reactivation of HBV: prophylaxis or treatment?Restoration of immunity and reactivation of hepatitis B virus after immunosuppressive therapy in a patient with severe aplastic anaemia.Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.Immunomodulatory therapy for Crohn's disease resulting in acute liver failure.Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.Significance of liver histology in HBsAg-positive, IgM anti-HBc-negative acute hepatitis B virus-related hepatitis.A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.Lamivudine treatment in a patient with hepatitis B virus reactivation after allogenic peripheral bone marrow transplantation.Clinical significance of antibody against hepatitis B virus core antigen in patients with hepatitis C virus-related hepatocellular carcinoma.
P2860
Q24240881-080AE237-E99A-45F9-A759-7B4D32BC6EBBQ33369855-74752C5C-A992-4A67-8434-739DD6FC8359Q33825391-1BD4F24B-34E6-42D6-9ACE-FC76DFDD0279Q34394777-79816202-9B06-4014-BAAA-953541FD53F8Q34734311-2EBB243C-D594-4F6A-B912-E7B34F8E3D4FQ34974883-E32DBEEA-29AB-469E-BD81-3AD3791C3BC7Q35057889-12DD069F-A4C9-4A63-8044-DF4C3A529C1DQ35095916-5BDE5D53-7F71-4C7D-BE78-C38718827211Q35152610-A7D5F001-A4BE-489E-8AA7-1DF10C201D31Q35584210-E1A5CCFA-EE99-45C3-BDC8-7740B5AE1987Q35875680-C42B0543-6445-41E0-A109-739845805341Q36213915-001B0B36-15BE-47AF-B930-1AB47A10A4A2Q36220459-F353AFB4-D08D-46E8-9FE2-0752D2810E03Q36368747-21940AC3-75E0-4F20-89BC-7638BC16CB2AQ36406054-CEEE9280-576A-4E9C-85F8-7FE1D4766DAEQ36597776-66762073-75C7-433B-913E-2AD95A3B90DDQ36957087-856E49F5-17E7-4745-802B-E84E1797005CQ37583193-49D28C3C-2EF2-44D4-8A1F-FE0EB5C87D6AQ37764963-42C4ACD5-C20C-4B9F-AA74-6CF9574F412AQ37978202-10CB0B2C-493A-478A-98FD-50A51BBD7AA0Q38253568-D7421584-BDC8-4DFE-A25F-E6B2A310347BQ38996149-884CE76E-3164-4230-A529-5AC13927AAB8Q40606238-F2E6C3B6-B523-49AB-B936-D164210625C1Q40642803-1BF39F7D-0D62-4A4D-962F-81A8D73BD6D8Q41859437-36E17487-F1F5-4CB9-B8E6-2E660F74898AQ42590960-BCAE4EF2-2728-430B-B9DD-2D12727EEDECQ43831214-B2EF7A27-2A3C-4358-ABD8-0DF73D359D99Q43982840-AAFB0076-2828-4387-A99B-18134FA564F0Q43996300-2B37A087-E057-4130-BCC1-9DB64EDB624FQ44874488-4DFC99C2-383E-423B-A01E-FE7B0FFE971DQ45164423-044F4AED-5515-43BC-9992-61946C2DD4E8Q45207581-4DCA02BB-30AD-4E75-89BB-4B40366E48CAQ45268408-55844E8E-2C3A-465C-8FC1-287A103B8EA5Q45355596-CE468F7B-11FF-42E2-B2A3-7DFB11ABBC19Q45367828-04B9AA07-A378-4239-9BB7-6A5D5698C98CQ45413414-0840B360-64B6-4E0D-BE75-A618DAFC2291Q45435711-B0FCB38B-73D1-4A8F-A260-8EF39D2FEDA3Q45722380-B56B32E0-1925-4ADC-8097-CB5D8D47AF65
P2860
Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Prevalence of hepatitis B viru ...... n patients with solid tumours.
@ast
Prevalence of hepatitis B viru ...... n patients with solid tumours.
@en
type
label
Prevalence of hepatitis B viru ...... n patients with solid tumours.
@ast
Prevalence of hepatitis B viru ...... n patients with solid tumours.
@en
prefLabel
Prevalence of hepatitis B viru ...... n patients with solid tumours.
@ast
Prevalence of hepatitis B viru ...... n patients with solid tumours.
@en
P2093
P2860
P356
P1476
Prevalence of hepatitis B viru ...... n patients with solid tumours.
@en
P2093
Alexopoulos CG
Hatzidimitriou G
Vaslamatzis M
P2860
P2888
P356
10.1038/SJ.BJC.6690652
P407
P577
1999-09-01T00:00:00Z
P5875
P6179
1049314063